ABCSG 64 / neoGRACE Overview
An open-label, two-arm, randomized phase II study of Sacituzumab Govitecan vs Standard of Care as neoadjuvant therapy for endocrine non-responsive ER+/HER2-negative early breast cancer
| Study start: | Q4/2026 |
| Coordinating Investigators: | Christian Singer, Vienna Michael Gnant, Vienna |
| Sample size: | 80 (national) |
| Study design: (Click to enlarge) |
 |
Share on